The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 1, 2006, Pages 27-35

  Dutton, Amanda ^a   Young, Lawrence S ^a   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cellular flice inhibitory protein (c FLIP); Gene therapy; Hodgkin's lymphoma (HL); RNA interference

Indexed keywords

ANTINEOPLASTIC AGENT; ATELOCOLLAGEN; CD30 ANTIGEN; DEATH RECEPTOR; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOSOME; OLIGONUCLEOTIDE; PROTAMINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL PROTECTION; CELL SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENE OVEREXPRESSION; GENE THERAPY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LYMPHOMA CELL; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS VECTOR;

ANIMALS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; GENE THERAPY; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS;

EID: 33144481343     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.1.27     Document Type: Review

References (96)

1. IGNEY FH, KRAMMER PH: Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer (2002) 2:277-288.
2. THORNBERRY NA, LAZEBNIK Y: Caspases: enemies within. Science (1998) 281:1312-1316.
3. HUANG DS, STRASSER A: BH3-only proteins- essential initiators of apoptonic cell death. Cell(2000) 103:839-842.
4. ZOU H, LI Y, LIU X, WANG X: An APAF-1: Cytochrome c multimeric complex is a functional apoptosome that activates Procaspase-9. J. Biol. Chem. (1999) 274:11549-11556.
5. CAIN K, BROWN DG, LANGLAIS C, COHEN GM: Caspase activation involves the formation of the aposome, a large (70 kDa) caspase-activating complex. J. Biol. Chem. (1999) 274:22686-22692.
6. LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 104:487-501.
7. ITOH N, YONEHARA S, ISHII A et al.: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 66:233-243.
8. NAGATA S, GOLSTEIN P: The Fas death factor. Science (1995) 267:1449-1456.
9. ARASE H, ARASE N, SAITO T et al.: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. (1995) 181:1235-1238.
10. ROUVIER E, LUCIANI MF, GOLDSTEIN et al.: Fas involvement in Ca(2+) independent T cell mediated cytotoxicity. J. Exp. Med. (1993) 177:195-200.
11. GRIFFITH TS, BRUNNER T, FLETCHER SM, GREEN DR, FERGUSON TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 270:1189-1192.
12. CHINNAIYAN AM, TEPPER CG, SELDIN MF et al.: FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumour necrosis factor receptor-induced apoptosis. J. Biol. Chem. (1996) 271:4961-4965.
13. KISCHKEL FC, HELLBARDT S, BEHRMANN I et al.: Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signalling complex (DISC) with the receptor. EMB0 J. (1995) 14:5579-5588.
14. KISCHKEL FC, LAWRENCE DA, TINEL A et al.: Death receptor recruitment of endogenous Caspase-10 and apoptosis initiation in the absence of Caspase-8, J. Biol. Chem. (2001) 276:46639-46646.
15. SHI Y: Caspase activation: revisiting the induced proximity model. Cell (2004) 117:855-858.
16. BOATRIGHT KM, RENATUS M, SCOTT FL et al.: A unique model for apical Caspase activation. Mol. Cell (2003) 11:529-541.
17. DONEPUDI M, MAC SWEENEY A, BRIAND C, GRUTTER MG: Insights into the regulatory mechanism for Caspase-8 activation. Mol. Cell (2003) 11:543-549.
18. SMYTH MJ, TAKEDE K, HAYAKAWA Y et al.: Nature's TRAIL -on a path to cancer immunotherapy. Immunity (2003) 18:1-6.
19. SPRICK MR, WEIGAND MA, REISER E et al.: FADD/MORT1 and Caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 12:599-609.
20. KISCHKEL FC, LAWRENCE DA, CHUNTHARAPAI A, SCHOW P, KIM KJ, ASHKENAZI A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and Caspase 8 to death receptors 4 and 5. Immunity (2000) 12:611-620.
21. KELLEY SK, ASHKENAZI A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. (2004) 4:333-339.
22. BOURALEXIS S, FINDLAY DM, EVDOKIOU A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis (2005) 10:35-51.
23. LIU X, YUE P, KHURI FR, SUN SY: Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. (2005) 65:9169-9175.
24. ASHKENAZI A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily, Nat. Rev. Cancer (2002) 2:420-430.
25. THOME M, SCHNEIDER P, HOFMANN K et al.: Viral FLICE-inhibitory protein (FLIPs) prevents apoptosis induced by death receptors. Nature (1997) 386:517-521.
26. IRMLER M, THOME M, HAHNE M et al.: Inhibition of death receptor signals by cellular FLIP. Nature (1997) 388:190-195.
27. SHU HB, HALPIN DR, GOEDDEL DV: Casper is a FADD- and caspase-related inducer of apoptosis. Immunity (1997) 6:751-763.
28. HU S, VINCENZ C, NI J, GENTZ R, DIXIT VM: I-FLICE, a novel inhibitor of tumour necrosis factor-1 and CD-95-induced apoptosis. J. Biol. Chem. (1997) 273:17255-17257.
29. SRINIVASULA SM, AHMAD M, OTTILIES S et al.: FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J. Mol. Chem. (1997) 272:18542-18545.
30. GOLTSEV YV, KOVALENKO AV, ARNOLD E et al.: CASH, a novel caspase homolgue with death effector domains. J. Biol. Chem. (1997) 272:19641-19644.
31. INOHARA N, KOSEKI T, HU Y, CHEN S, NUNEZ G: CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc. Natl. Acad. Sci. USA (1997) 94:10717-10722.
32. HAN DK, CHAUDHARY PM, WRIGHT ME et al.: MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc. Natl. Acad. Sci. USA (1997) 94:11333-11338.
33. RASPER DM, VAILLANCOURT JP, HADANO S et al.: Cell death attenuation by 'Usurpid, a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by CD-95 (Fas, APO-1) receptor complex. Cell. Death. Differ. (1998) 5:271-288.
34. SCAFFIDI C, SCHMITZ I, KRAMMER PH, PETER ME: The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. (1999) 274:1541-1548.
35. KRUEGER A, SCHMITZ I, BAUMANN S, KRAMMER PH, KIRCHHOFF S: Cellular FLICE-inhibitory protein splice variants inhibit different steps of Caspase 8 activation at the CD95 death induced signalling complex. J. Biol. Chem. (2001) 276:20633-20640.
36. R, a new regulator death receptor-induced apoptosis. J. Biol. Chem. (2005) 280:14507-14513.
37. MICHEAU O, THOME M, SCHNEIDER P et al.: The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signalling complex. J. Biol. Chem. (2002) 277:45162-45171.
38. BOATRIGHT KM, DEIS C, DENAULT DP, SALVESEN GS: Activation of caspases-8 and -10 by FLIPL. Biochem. J. (2004) 382:651-657.
39. CHANG DW, XING Z, PAN Y et al.: c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. (2002) 21:3704-3714.
40. MEDEMA JP, DE JONG J, VAN HALL T, MALIEF CJ, OFFRINGA R. Immune escape of tumours in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. (1999) 190:1033-1038.
41. DJERBI M, SCREPANTI V, CATRINA AL, BOGEN B, BIBERFELD P, GRANDIEN A: FLICE-inhibitory protein defines a new class of tumour progression factors. J. Exp. Med. (1999) 190:1025-1032.
42. DUTTON A, O'Neil JD, MILNER AE et al.: Expression of the Cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc. Natl. Acad. Sci. USA (2004) 101:6611-6616.
43. MATHAS S, LIETZ A, ANAGNOSTOPOULOS et al.: c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J. Exp. Med. (2004) 199:1041-1052.
44. GANTER TM, HAAS TL, SYKORA J et al.: Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell. Death Diff. (2004) 11:S86-S96.
45. RIPPO MR, MORRETTI S, VESCOVI S et al.: FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene (2004) 23:7753-7760.
46. SHARP DA, LAWRENCE DA, ASHKENAZI A: Selective knockdown of the long variant of Cellular FLICE inhibitory protein augments death receptor-mediated Caspase-8 activation and apoptosis. J. Biol. Chem. (2005) 280:19401-19409.
47. OKANO H, SHIRAKI K, INOUE H et al.: Cellular FLICE/Caspase-8-inhibitory protein as a principle regulator of cell death and survival in human hepatocellular carcinoma. Lab. Invest. (2003) 83:1033-1043.
48. SHIVAPURKAR N, REDDY J, MATTA H et al.: Loss of expression of death-inducing signalling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene (2002) 21:8510-8514.
49. ELNEMR A, OHTA T, YACHIE A et al.: Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int. J. Oncol. (2001) 18:311-316.
50. BULLANI RR, HUARD B, VIARD-LEVEUGLE I et al.: Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. (2001) 117:360-364.
51. RYE BK, LEE MG, CHI SG et al.: Increased expression of cFLIP (L) in colonic adenocarcinoma. J. Pathol. (2001) 194:15-19.
52. BAUMLER C, DUAN F, ONEL K et al.: Differential recruitment of Caspase 8 to cFLIP confers sensitivity or resistance to Fas mediated apoptosis in a subset of familial lymphoma patients. Leuk. Res. (2003) 27:841-851.
53. THOMAS RK, KALLENBORN A, WICKENHAUSER C: Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. (2002) 160:1521-1528.
54. SIEGMUND D, HADWIGER P, PFIZENMAIER K, VORNLOCHER HP, WAJANT H: Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitise tumour cells for TRAIL-induced apoptosis. Mol. Med. (2002) 8:725-732.
55. ASHKENAZI A, PAI RC, FONG S et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. Clin. Invest. (1999) 104:155-162.
56. WALCZAK H, MILLER RE, ARIAIL K et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. (1999) 5:157-163.
57. GRIFFITH TS, CHIN WA, JACKSON GC, LYNCH DH, KUBIN MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. (1998) 161:2833-2840.
58. LEVERKUS M, MEUMANN M, MENGLING T et al.: Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. (2000) 60:553-559.
59. MICHEAU O, LENS S, GOUDE O, ALEVIZOPOULAS K, TSCHOPP J: NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. (2001) 21:85299-5305.
60. SUHARA T, MANO T, OLIVEIRA B, WALSH K: Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ. Res. (2001) 89:13-19.
61. YEH JH, HSU SC, HAN SH, LAI MZ: Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression. J. Exp. Med. (1998) 188:1795-802.
62. HU W, JOHNSON H, SHU HB: Activation of NF-κB by FADD, Casper, and Caspase-8. J. Biol. Chem. (2000) 275:10838-10844.
63. KATAOKA T, BUDD RC, HOLLER N et al.: The caspase-8 inhibitor FLIP promotes activation of NF-κ and Erk signaling pathways. Curr. Biol. (2000) 10:640-648.
64. CHAUDHARY PM, EBY MT, JASMIN A, KUMAR A, LIU L, HOOD L: Activation of the NF-κB pathway by caspase 8 and its homologs. Oncogene (2000) 19:4451-4460.
65. KATAOKA T, TSCHOPP J: N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway. Mol. Cell. Biol. (2004) 24:2627-2636.
66. KREUZ S, SIEGMUND D, RUMPF JJ et al.: NfkappaB activation by Fas is mediated through FADD, Caspase-8, and RIP and is inhibited by FLIP. J. Cell. Biol. (2004) 166:369-380.
67. L inhibits tumour necrosis factor-related apoptosis-inducing ligand-mediated NF-κB activation at the death signaling complex in human keratinocytes. J. Biol. Chem. (2004) 51:52824-52834.
68. ZHANG N, HE YW: An essential role for c-FLIP in the efficient development of T lymphocytes. J. Exp. Med. (2005) 202:395-404.
69. WHITEHEAD E, SHALET SM, BLACKLEDGE G: The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer (1982) 49:418-422.
70. WHITEHEAD E, SHALET SM, BLACKLEDGE G et al.: The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer (1983) 52:988-992.
71. HANCOCK SL, TUCKER MA, HOPPE RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA (1993) 270:1949-1955.
72. WOLDEN S, LAMBOURN KR. CLEARY SF et al.: Second cancers following pediatric Hodgkin's disease. J. Clin. Oncol. (1998) 16:536-544.
73. FRIEDMANN AM, HUDSON MM, WEINSTEIN HJ et al.: Treatment of unfavourable childhood Hodgkins disease with VEPA and low dose, involved-field radiation. J. Clin. Oncol. (2002) 20:3088-3094.
74. DONALDSON SS: Pediatric Hodgkin's disease-up, up, and beyond. Int. J. Radiat. Oncol. Biol. Phys. (2002) 54:1-8.
75. KANZLER H, KUPPERS R, HANSMANN ML, RAJEWSKY K: Hodgkin and Reed/Sternberg cells in Hodgkins disease represent the outgrowth of a dominant tumour done derived from (crippled) germinal centre B cells. J. Exp. Med. (1996) 184:1495-1505.
76. MACLENNAN ICM: Germinal centres. Ann. Rev. Immunol. (1994) 12:117-139.
77. LIU YL, GROUARD G, DE BOUTEILLER O, BANCHEREAU J: Follicular dendritic cells and germinal centres. Int. Rev. Cytol. (1996) 166:139-179.
78. HOLDER MJ WANG H, MILNER AE et al.: Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur. J. Immunol. (1993) 23:2368-2371.
79. GORDON J: CD40 and its ligand: central players in B lymphocyte survival, growth and differentiation. Blood Rev. (1995) 9:53-56.
80. KEHRY MR: CD40-mediated signalling in B cells. Balancing cell survival, growth and death. J. Immunol. (1996) 56:345-348.
81. POUND JD, GORDON J: Maintenance of human germinal centre B cells in vitro. Blood (1997) 89:919-928.
82. CLEARY AM, FORTUNE SM, YELLIN MJ, CHESS L, LEDERMAN S: Opposing roles of CD95 (Fas/APO-1) and CD40 in death and rescue of human low density tonsillar B cells. J. Immunol. (1995) 155:3329-3337.
83. TAKAHASHI Y, OHTA H, TAKEMORI T: Fas is required for clonal selection in germinal centres and the subsequent establishment of the memory B cell repertoire. Immunity (2001) 14:181-192.
84. SIDDIQA A, SIMS-MOURTADA JC, GUZMAN-ROJAS L et al.: Regulation of CD40 and CD40 ligand by AT-hook transcription factor ANKA. Nature (2001) 410:383-387.
85. MARTINEZ-VALDEZ H, GURET C, DE BOUTEILLER O, FUGIER I BANCHEREAU J, LIU YJ: Human germinal centre B cells express die apoptosis inducing gcnes fas, c-myc, p53 and Bax but not the survival gene bck-2. J. Exp. Med. (1996) 183:971-977.
86. VAN EIJK M, DEFRANCE T, HENNINO A, DE GROOT C: Death-receptor contribution to the germinal-centre reaction. Trends Immunol. (2001) 22:677-682.
87. XERRI L, CARBUCCIA N, PARC P, HASSOUN J, BIRG F: Frequent expression of Fas/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology (1995) 27:235-241.
88. METKAR SS, NARESH KN, REDKAR AA, SOMAN CS, ADVANI SH, NADKARNI JJ: Expression of Fas and Fas ligand in Hodgkins disease. Leuk. Lymphoma (1999) 33:521-530.
89. MUSCHEN M, RE D, BRAUNIGER A et al.: Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res. (2000) 60:5640-5643.
90. MAGGIO EM, VAN DEN BERG A, DE JONG D, DIEPSTRA A, POPPEMA S: Low frequency of Fas mutations I Reed-Sternberg cells of Hodgkin's lymphoma. Am. J. Pathol. (2003) 162:29-35.
91. SIOUD M: siRNA delivery in vivo. Methods Mol. Biol. (2005) 309:237-249.
92. TAKEI Y, KADOMATSU K, YUZAWA Y et al.: Small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. (2004) 64:3365-3370.
93. MORRISSEY DV, LOCKRIDGE JA, SHAW L et al.: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. (2005) 23:1002-1007.
94. SCHIFFELERS RM, ANSARI A, XU J et al.: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. (2004) 32:e149.
95. SONG E, ZHU P, LEE SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotech. (2005) 23:709-717.
96. KARAGIANNIS TC, EL-OSTA A: RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther. (2005) 12:787-795.